Trial Profile
A Randomized Phase II Study of Erlotinib Compared to Single Agent Chemotherapy-Erlotinib Combination in Pretreated Patients With Advanced NSCLC (NVALT10 Study).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Sep 2020
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Erlotinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NVALT-10
- 28 Aug 2013 Results published in the Annals of Oncology.
- 02 Oct 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
- 02 Oct 2012 Patients were enrolled between March 2009 and December 2011 according to the abstract.